<DOC>
	<DOCNO>NCT01472289</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy concentrate autologous bone marrow derive stem cell treatment Critical Limb Ischemia patient .</brief_summary>
	<brief_title>Safety Efficacy Autologous Bone Marrow Mononuclear Cells Patients With Severe Critical Limb Ischemia</brief_title>
	<detailed_description>A total 15 patient suffer end stage IV V Rutherford /CLI previous therapeutic strategy fail ( e.g . surgical revascularization ) select undergo local transplantation autologous BMMNCs . Conventional treatment include angioplasty /or bypass remove blood vessel blockage restore blood supply , along prescribe medicine aid ulcer recovery wound heal debridement damaged/infected tissue . Amputation inevitable many case blood capillary correct restenosis vessel common . Cell therapy mononuclear cell patient bone marrow promising stem cell capable stimulate regenerate capillary blood vessel ( neovascularization ) . This Phase Ib ( feasibility study ) , prospective , non randomize open label study aim find safety efficacy intramuscular autologous bone marrow mononuclear cell implantation patient chronic critical limb ischemia . The efficacy/safety therapy assess use several endpoint ( ) prevention amputation , ( b ) wound healing ( c ) degree angiogenesis . In order ass limb ischemia , measurement perform pre- post transplantation variety time interval . The measurement include : ABI-ankle brachial index , Transcutaneous partial pressure Oxygen ( TcPO2 ) , 6 min walk test , Rest pain intermittent Claudication assessment , Healing ulcers/ wound angiography affect limb .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Atherosclerotic ischemic peripheral vascular disease ( PVD ) Thromboangiitis Obliterans severe Critical Limb Ischemia ( Rutherford Category 4 5 : ischemic pain rest minor tissue loss Fontaine Class 4 : Ischemic ulcer gangrene , whivh may dry humid ) . A nonsurgical candidate revascularization e.g . prior vascular reconstruction , inability locate suitable vein grafting , diffuse multi segment disease , extensive infrapopliteal disease amenable vascular graft . Major amputation recommend patient due severe life threaten PAD . Subjects must maximal tolerated medical therapy peripheral vascular disease include A ) Cessation smoke B ) Referral endocrinologist control HgA1c &lt; 8 % mg/dl , C ) control hyperlipidemia statin antihyperlipidemic drug indicate , D ) control hypertension indicate E ) Antiplatelet therapy aspirin / cilostazol ( unless medically contraindicate , e.g . bleed allergy ) . Ankle Brachial Pressure Index ( ABI ) ≤ 0.6 ankle systolic pressure ≤ 60 mm Hg TcPO2 ≤ 35 mmHg foot . Subjects able understand requirement study , willing provide voluntary write informed consent , abide study requirement , agree return require followup visit . Subjects CLI suitable surgical percutaneous revascularization Subjects acute chronic inflammatory condition . CLI patient require amputation proximal transmetatarsal level Subjects spread ( wet ) gangrene Subjects gait disturbance reason CLI . Subjects poorly control diabetes mellitus . Subjects diagnose Thromboangiitis Obliterans ( Buerger 's Disease ) smokers unwilling unable quit smoking physician feel smoke cessation doubtful . Subjects moderate severe COPD GOLD Classification IIb III . Uncontrolled congestive heart failure Subjects leave ventricular ejection fraction &lt; 25 % AHA Stage C D heart failure NYHA Class IV CHF Stroke myocardial infarction within last 3 month . Subjects contraindicate CT Angiogram . Illnesses condition uncontrolled whose control , opinion Principal Investigator , may jeopardize participation study complication therapy . Documented terminal illness cancer concomitant disease process life expectancy le 1 year . Subjects already enrol another investigational drug trial complete within 3 month . History severe alcohol drug abuse within 3 month screen . Hb % &lt; 10 gm % ; Serum creatinine ≥ 2.0mg % ; Serum total bilirubin ≥2.0mg % ; HbA1c &gt; 8.0 % . Women child bear potential ; pregnant lactating woman . Subjects ) myocardial infarction within last 30 day leave ventricular ejection fraction &lt; 35 % , B ) Subjects cerebrovascular accident within last 6 month . INR &gt; 1.5 time Bone Marrow harvest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>CLI</keyword>
	<keyword>Peripheral arterial disease</keyword>
</DOC>